to chronic disease
Oliver Siegel is Chief Executive Officer (CEO) and Board Member of AFFiRiS AG. He joined AFFiRiS in 2014 and served in roles of increasing responsibility including Chief Operating Officer. Prior to joining AFFiRiS, Oliver was Managing Director and Head of Pharma at a leading Investment Bank NM Rothschild & Sons, London. Oliver has more than 15 year of experience in leading Investment Banks on strategy and fundraising for Pharma, Biotechnology and Healthcare Services companies. Oliver holds a degree in business administration from Otto-Friedrich-University Bamberg. Oliver contributes considerable experience in Strategy, Business Development and Corporate Finance.
Günther Staffler is Chief Technology Officer (CTO) and Member of the Executive Board of AFFiRiS. Prior to his appointment to the Executive Board Günther led the Immunology Department. Günther Staffler completed his degree in biochemistry and immunology at the Institute for Immunology of University of Vienna. He has also been a lecturer at the University of Vienna (1997-2001). After a postdoctoral stay at InterCell AG between 2001 and 2003 Dr. Staffler joined the biotech company Biovertis AG where he was first responsible in establishing the program for identification of essential genes in different pathogenic organisms. Besides setting up the microbiology department he became also responsible for the preclinical development at Biovertis AG. During his research career Dr. Staffler has authored many publications in international journals and was awarded the “Förderungspreis” of the Austrian Society of Chemistry in 1996 and the “Ursula und Fritz Melcher’s Preis” of the Austrian Society of Immunology in 2003.